Cargando…
Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma
While mutations in the KRAS oncogene are amongst the most prevalent in human cancer, there are few successful treatments to target these tumors. It is also likely that heterogeneity in KRAS-mutant tumor biology significantly contributes to the response to therapy. We hypothesized that presence of co...
Autores principales: | Schabath, Matthew B., Welsh, Eric A., Fulp, William J., Chen, Lu, Teer, Jamie K., Thompson, Zachary J., Engel, Brienne E., Xie, Mengyu, Berglund, Anders E., Creelan, Ben C., Antonia, Scott J., Gray, Jhanelle E., Eschrich, Steven, Chen, Dung-Tsa, Cress, W. Douglas, Haura, Eric B., Beg, Amer A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4837098/ https://www.ncbi.nlm.nih.gov/pubmed/26477306 http://dx.doi.org/10.1038/onc.2015.375 |
Ejemplares similares
-
Early2 factor (E2F) deregulation is a prognostic and predictive biomarker in lung adenocarcinoma
por: Chen, Lu, et al.
Publicado: (2016) -
Application of Bayesian predictive probability for interim futility analysis in single-arm phase II trial
por: Chen, Dung-Tsa, et al.
Publicado: (2019) -
Utilization of target lesion heterogeneity for treatment efficacy assessment in late stage lung cancer
por: Chen, Dung-Tsa, et al.
Publicado: (2021) -
Strategies for power calculations in predictive biomarker studies in survival data
por: Chen, Dung-Tsa, et al.
Publicado: (2016) -
Randomized-controlled phase II trial of salvage chemotherapy after immunization with a TP53-transfected dendritic cell-based vaccine (Ad.p53-DC) in patients with recurrent small cell lung cancer
por: Chiappori, Alberto A., et al.
Publicado: (2018)